A phase I dose escalation study of LBQ707 (gimatecan) administered orally 5 consecutive days to Japanese patients with advanced solid tumor
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2012
At a glance
- Drugs Gimatecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 28 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 22 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
- 03 Jan 2007 New trial record.